Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity

[1]  G. Raghu,et al.  Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial , 2020, Arthritis & rheumatology.

[2]  G. Abignano,et al.  Biomarkers as an opportunity to stratify for outcome in systemic sclerosis. , 2020, European journal of rheumatology.

[3]  Choon-Sik Park,et al.  The S100 calcium-binding protein A4 level is elevated in the lungs of patients with idiopathic pulmonary fibrosis. , 2020, Respiratory medicine.

[4]  C. Denton,et al.  Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis , 2020, Arthritis & rheumatology.

[5]  Jing Geng,et al.  The autocrine CXCR4/CXCL12 axis contributes to lung fibrosis through modulation of lung fibroblast activity , 2020, Experimental and therapeutic medicine.

[6]  Seidai Sato,et al.  Fibrocytes and Fibroblasts - where are we now. , 2019, The international journal of biochemistry & cell biology.

[7]  M. Cutolo,et al.  Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study. , 2019, Rheumatology.

[8]  D. Riches,et al.  Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases , 2019, European Respiratory Journal.

[9]  S. Saraswati,et al.  Identification of a pro-angiogenic functional role for FSP1-positive fibroblast subtype in wound healing , 2019, Nature Communications.

[10]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[11]  Maurizio Cutolo,et al.  Pathophysiology of systemic sclerosis: current understanding and new insights , 2019, Expert review of clinical immunology.

[12]  T. Rodríguez-Reyna,et al.  Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast , 2019, BioMed research international.

[13]  M. Vonk,et al.  Unraveling SSc Pathophysiology; The Myofibroblast , 2018, Front. Immunol..

[14]  M. Cutolo,et al.  Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay , 2018, Arthritis Research & Therapy.

[15]  M. Kool,et al.  Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis , 2018, Respiratory Research.

[16]  M. Cutolo,et al.  Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts , 2018, Arthritis Research & Therapy.

[17]  M. Foley,et al.  Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis , 2018, Scientific Reports.

[18]  Shiwu Zhang,et al.  Role of metastasis-induced protein S100A4 in human non-tumor pathophysiologies , 2017, Cell & Bioscience.

[19]  Seidai Sato,et al.  Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity , 2017, Respiratory Research.

[20]  G. Riemekasten,et al.  Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases , 2017, Nature Reviews Rheumatology.

[21]  C. Maier,et al.  Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis , 2017, Annals of the rheumatic diseases.

[22]  T. Scheper,et al.  Disease-related autoantibody profile in patients with systemic sclerosis , 2017, Autoimmunity.

[23]  E. Taraldsrud,et al.  Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort , 2017, The Journal of Rheumatology.

[24]  D. Abraham,et al.  Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis , 2016, Arthritis & rheumatology.

[25]  S. Madala,et al.  Mechanisms of Lung Fibrosis Resolution. , 2016, The American journal of pathology.

[26]  C. Foocharoen,et al.  Clinical differences between Thai systemic sclerosis patients with positive versus negative anti‐topoisomerase I , 2016, International journal of rheumatic diseases.

[27]  R. Bucala.  Fibrocytes at 20 Years , 2015, Molecular medicine.

[28]  G. Riemekasten,et al.  Functional Autoantibodies in Systemic Sclerosis Pathogenesis , 2015, Current Rheumatology Reports.

[29]  G. Schett,et al.  Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[30]  A. Wells,et al.  Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis , 2014, Arthritis & rheumatology.

[31]  H. Collard,et al.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[32]  C. Feghali-Bostwick,et al.  Fibroblasts in fibrosis: novel roles and mediators , 2014, Front. Pharmacol..

[33]  S. Hoffman,et al.  Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry , 2014, Front. Pharmacol..

[34]  C. Denton,et al.  Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells , 2013, Arthritis Research & Therapy.

[35]  M. Trojanowska,et al.  Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis , 2012, Arthritis Research & Therapy.

[36]  C. Denton,et al.  Autoantibodies as predictive tools in systemic sclerosis , 2010, Nature Reviews Rheumatology.

[37]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.